2025年跨国药企年报悉数落定,全球制药行业的格局博弈远比2024年更具颠覆性,一众 MNC的发展迷局终迎答案,而新的行业考题也同步浮出水面。礼来凭GLP-1赛道的绝对爆发力一路狂飙,跃升登顶全球制药榜首,成为五年间首位新科王者;同时也是全球药企市值第一,并手握新药王“替尔泊肽”。默沙东虽有K药这一肿瘤王牌,却难逃HPV疫苗在中国市场的断崖式下滑,业绩暴跌位次大挫,昔日爆款成拖垮业绩的软肋。老牌...
Source Link2025年跨国药企年报悉数落定,全球制药行业的格局博弈远比2024年更具颠覆性,一众 MNC的发展迷局终迎答案,而新的行业考题也同步浮出水面。礼来凭GLP-1赛道的绝对爆发力一路狂飙,跃升登顶全球制药榜首,成为五年间首位新科王者;同时也是全球药企市值第一,并手握新药王“替尔泊肽”。默沙东虽有K药这一肿瘤王牌,却难逃HPV疫苗在中国市场的断崖式下滑,业绩暴跌位次大挫,昔日爆款成拖垮业绩的软肋。老牌...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.